Juvenescence is pleased to announce its latest equity investment in BYOMass Inc., a Massachusetts-based company focused on central control of metabolism in the context of aging and age-related diseases. Juvenescence will provide BYOMass with up to $6.5 million in equity financing and collaborate with BYOMass to advance these programs.
Juvenescence is also delighted to announce that Dr Margaret Jackson, the CEO of BYOMass, has joined the Juvenescence team as Vice President, Head of Preclinical Research and Development. Dr Jackson has almost twenty years of drug discovery experience, having led multiple projects from early discovery into clinical trials. Prior to forming BYOMass, she was Senior Director, Head of Eating Disorders and served on the Cardiovascular and Metabolism leadership team at Pfizer.
“Chronic disease is a tremendous burden on our healthcare system and economy, and we are excited by the potential for BYOMass to make an impact on this colossal problem,” said Dr. Gregory Bailey, “We are also thrilled to see Dr Margaret Jackson join the Juvenescence team and help bring the life-changing therapies we are developing at Juvenescence one step closer to patients.”
Dr. Jackson said, “I am delighted to join Juvenescence and advance their mission helping people live longer, healthier lives. I am also excited that BYOMass’s therapeutic programs will benefit from the ecosystem Juvenescence is building to accelerate the discovery and development of novel therapeutics.”